Postirradiation Sarcoma: Clinicopathologic Features and Role of Chemotherapy in the Treatment Strategy

Abstract EN

Purpose.

An analysis of the clinicopathologic features and treatment of patients was performed to guide evaluation and management of postirradiation sarcoma.

Patients and Methods.

Between 1994 and 2001, 25 patients with postirradiation sarcoma were treated in one center with different chemotherapy, mainly in neoadjuvant setting (19).

Tumors for which these patients received radiotherapy initially were mainly breast carcinoma (for 15 patients).

The postirradiation sarcomas were of different histopathologic forms, most frequently osteosarcoma, leiomyosarcoma, and angiosarcoma.

Results.

Of the 25 patients, 19 were initially treated with chemotherapy.

Nine of 19 pretreated patients achieved clinical partial response (RP = 47%).

Leiomyosarcomas were good responders (3/4) and undifferentiated sarcoma (3/5).

Responders were more often treated with MAID (6/8).

Eight of the 9 responders underwent surgery.

Two patients achieved complete histological response.

Seven of the 9 good responders are alive with a median follow up of 24 months.

For all treated patients, median follow up 24 months (6–84 months), overall survival and disease free survival were, respectively, 17/25 (68%), and 14/25 (56%).

Conclusion.

From our data, postirradiation sarcoma should not be managed differently from primary sarcoma.

Chemotherapy has to be included in the treatment plan of postirradiation sarcoma, in future studies.